Source: Global Wellness Summit
  • Psyence Group (PSYG) will break new ground as the first psychedelic company invited to speak at the 15th Annual Global Wellness Summit
  • The summit, taking place in Boston from November 30 to December 3, 2021, includes doctors, activists, and health care executives
  • Psyence’s Head of Corporate Social Responsibility, Mary-Elizabeth Gifford will host an in-person keynote conversation with Rick Doblin, PhD on December 1 at 4:10 pm EST
  • Psyence is a public life science biotechnology company focused on natural psychedelics
  • Psyence Group Inc. (PSYG) is unchanged on the day, trading at C$0.19 per share at 11:15 am EST

Psyence Group (PSYG) will break new ground as the first psychedelic company invited to speak at the 15th Annual Global Wellness Summit.

The summit, taking place in Boston from November 30 to December 3, 2021, includes doctors, activists, and health care executives from a variety of research organizations including Harvard, MIT and Cleveland Clinic.

Psyence’s Head of Corporate Social Responsibility, Mary-Elizabeth Gifford will host an in-person keynote conversation with Rick Doblin, Ph.D., Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS) on the future of psychedelics and healing. The conversation with Doblin is scheduled for December 1st at 4:10 pm EST.

A psychedelic researcher and activist, Rick Doblin is widely recognized for his work de-stigmatizing psychedelics through evidence-based scientific research. His organization, MAPS, is sponsoring Phase 3 clinical trials of MDMA-assisted therapy for PTSD.

Mary-Elizabeth Gifford, chair of the non-profit Global Wellness Institute’s Psychedelics & Healing Initiative, leads Corporate Social Responsibility for the Psyence Group, where she works to democratize responsible psychedelic and nature-based solutions for mental health and wellness that also help heal and strengthen the wider community.  

Psyence is a public life science biotechnology company focused on natural psychedelics. Psyence works with natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care.

Psyence Group Inc. (PSYG) is unchanged on the day, trading at C$0.19 per share at 11:15 am EST.

More From The Market Online

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.